Depomed Company Profile (NASDAQ:DEPO)

Depomed trades on the NASDAQ under the ticker symbol "DEPO."

Depomed, Inc. (NASDAQ:DEPO) issued its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $0.18. The company had revenue of $95 million for the quarter, compared to the consensus estimate of $99.48 million. Depomed had a negative return on equity of 25.33% and a negative net margin of 21.41%. The firm's revenue was down 9.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.04 EPS. View Depomed's Earnings History.

Depomed is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for Depomed.

8 analysts have issued 12 month price targets for Depomed's stock. Their predictions range from $10.00 to $26.00. On average, they expect Depomed's share price to reach $17.00 in the next year. View Analyst Ratings for Depomed.

Here are some recent quotes from research analysts about Depomed stock:

• 1. Cantor Fitzgerald analysts commented, "After the March 28 close, DEPO announced an agreement with Starboard that replaces CEO Jim Schoeneck as well as two incumbent board members. Guidance for 1Q17 revenue was also released, $95-100M vs. FactSet estimate." (3/29/2017)
• 2. Janney Montgomery Scott analysts commented, "Recent developments in the 2013 patent litigation brought by DEPO against Purdue have resulted in DEPO filing an amended complaint claiming Purdue willfully violated its patents. The dispute pertains to DEPO's claim that Purdue's abuse-deterrent formulation of OxyContin, which was approved by the FDA on April 5, 2010 and subsequently commercialized, relies on inventions protected by patents for DEPO's Acuform?? drug delivery technology. With a potential royalty on cumulative net sales of $10 billion at stake, we have previously estimated, and continue to believe, a damage award of $200 million or more is possible, with little to no downside risk to DEPO in the process. We note our prior estimate did not contemplate an enhanced damage award that may result in a treble (3x) damages if DEPO prevails." (2/27/2017)
• 3. Mizuho analysts commented, "We had expected some benefit from stocking in the quarter that did not materialize. Mgmt also lowered its FY:16 revenue guidance from $490-$520M to $480-$505M and tightened its earnings guidance towards the lower end of the prior range (non-GAAP adjusted Earnings are now $95-$105M, down from $95-$115M previously). We were modeling $488.8M in revenues and $84M in net income so the lowered guide is ultimately not that surprising. We will revisit our Buy rating and $23 PT after the earnings call. Product updates: Nucynta/ER sales of $71.9M (26.9% Y/Y growth) missed consensus estimates of $75.5M. Gralise revenues came in at $23.8M relative to $22.1M consensus, growing 13.7% Y/Y. We view this uptick as a sign that mgmt’s efforts to revitalize the brand have been somewhat effective. Zipsor sales of $6.8M (+13.8% Y/Y) beat consensus estimates of $6.4M due to the introduction of a 120 pill bottle (that led to a higher pill count or greater value per prescription). Cambia sales of $7.6M missed consensus estimates of $8.2M but the brand is still growing 11.2% Y/Y. Finally, Lazanda sales of $6.4M beat consensus estimates of $5.8M, and the brand grew 64.9% Y/Y. Activist updates: We expect an investor presentation from Starboard Value during its proxy solicitation period that could drive additional momentum in the stock." (8/4/2016)

Depomed saw a decline in short interest during the month of June. As of June 15th, there was short interest totalling 11,036,089 shares, a decline of 12.1% from the May 31st total of 12,559,484 shares. Based on an average trading volume of 1,531,458 shares, the days-to-cover ratio is currently 7.2 days. Approximately 18.0% of the shares of the company are short sold.

Some companies that are related to Depomed include Global Blood Therapeutics (GBT), Natus Medical Incorporated (BABY), Acceleron Pharma (XLRN), Quidel Corporation (QDEL), Momenta Pharmaceuticals (MNTA), Dermira (DERM), Medpace Holdings (MEDP), ABAXIS (ABAX), LHC Group (LHCG), The Ensign Group (ENSG), Genomic Health (GHDX), Xencor (XNCR), Amarin Corporation PLC (AMRN), Eagle Pharmaceuticals (EGRX), Community Health Systems (CYH), Aimmune Therapeutics (AIMT), Esperion Therapeutics (ESPR) and Quality Systems (QSII).

Depomed's management team includes the folowing people:

• James P. Fogarty CPA, Chairman of the Board
• Arthur J. Higgins, President, Chief Executive Officer, Director
• August J. Moretti, Chief Financial Officer, Senior Vice President
• Matthew M. Gosling, Senior Vice President, General Counsel
• Sharon D. Larkin, Senior Vice President - Human Resources and Administration.
• Gerd G. Kochendoerfer, Senior Vice President, Technical Development & Quality
• Srinivas Gandham Rao M.D. Ph.D., Chief Medical Officer and Senior Vice President
• Thadd M. Vargas, Senior Vice President - Business Development
• Karen A. Dawes, Independent Director
• Louis J. Lavigne Jr., Independent Director

Depomed's stock is owned by a variety of of institutional and retail investors. Top institutional investors include STARBOARD VALUE LP (8.70%), Deltec Asset Management LLC (1.64%), ING Groep NV (0.70%), Creative Planning (0.06%), Louisiana State Employees Retirement System (0.04%) and Fox Run Management L.L.C. (0.04%). Company insiders that own Depomed stock include Arthur J Higgins, August J Moretti and Thadd M Vargas. View Institutional Ownership Trends for Depomed.

Depomed's stock was sold by a variety of institutional investors in the last quarter, including Deltec Asset Management LLC, Capstone Asset Management Co., Creative Planning and Wellington Shields Capital Management LLC. Company insiders that have sold Depomed stock in the last year include August J Moretti and Thadd M Vargas. View Insider Buying and Selling for Depomed.

Depomed's stock was purchased by a variety of institutional investors in the last quarter, including ING Groep NV, Fox Run Management L.L.C., Aperio Group LLC, State of Alaska Department of Revenue and Louisiana State Employees Retirement System. View Insider Buying and Selling for Depomed.

Shares of Depomed can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Depomed stock can currently be purchased for approximately $10.79.